Amiel Gross currently serves as Head of Legal at the Center for Breakthrough Medicines in Philadelphia, focusing on building and managing their legal functions. He is responsible for ensuring the business strategies and policies are aligned with all risks taken into consideration. Counselling executives and senior management, negotiating complex commercial transactions, facilitating strategic alliances, supporting a range of legal issues arising during highly-regulated biotechnology business operations - these topics highlight his work as an attorney who specialises in cell & gene therapy manufacturing.
This professional oversight responsibility and hands-on experience across an array of subjects. These subjects include licensing deals, master services agreements, procurement contracts, intellectual property, corporate affairs, sponsored R&D collaborations, FDA regulatory and compliance, litigation, labour and employment, cyber-security and privacy.
Amiel Gross studied International Law at the Queen Mary University of London. He holds a Bachelor of Arts Degree from Southwestern University and a Doctor of Law Degree from The University of Texas School of Law.
His skills include general corporate counsel, life science industry, biotechnology, industry knowledge, pharmaceutical law, bio pharmaceuticals, corporate law, licensing, regulatory compliance. He is also highly experienced at business transactions, commercial contracts, CDMO, CGT, cell and gene therapy.
Philadelphia, PA, USA https://www.crunchbase.com/person/amiel-gross
June 2020 - Present
Amiel Gross serves as Head of Legal at the Center for Breakthrough Medicines at Philadelphia since 2020. He focuses on building and managing the legal function of a rapidly growing biotechnology company in cell and gene therapy manufacturing.
January 2020 - May 2020
Managed internal legal matters for Discovery Labs, a life science real estate holding company, in connection with the spinoff of its core operating business, Center for Breakthrough Medicines, a biotech startup focused on outsourced end-to-end manufacturing of Cell & Gene Therapy drug products.
August 2009 - October 2014
Senior Associate at Dentons, a global law firm driven to provide you with the competitive edge in an increasingly complex and interconnected marketplace.
January 2001 - November 2006
Associate at Orrick, Herrington & Sutcliffe LLP, a global law firm focused on serving the technology & innovation, energy & infrastructure and finance sectors.
2004 - 2006
2002 - 2005
1999 - 2002
Amiel Gross currently serves as Head of Legal at the Center for Breakthrough Medicines in Philadelphia, focusing on building and managing their legal functions. He is responsible for ensuring the business strategies and policies are aligned with all risks taken into consideration. Counselling executives and senior management, negotiating complex commercial transactions, facilitating strategic alliances, supporting a range of legal issues arising during highly-regulated biotechnology business operations - these topics highlight his work as an attorney who specialises in cell & gene therapy manufacturing.
This professional oversight responsibility and hands-on experience across an array of subjects. These subjects include licensing deals, master services agreements, procurement contracts, intellectual property, corporate affairs, sponsored R&D collaborations, FDA regulatory and compliance, litigation, labour and employment, cyber-security and privacy.
Amiel Gross studied International Law at the Queen Mary University of London. He holds a Bachelor of Arts Degree from Southwestern University and a Doctor of Law Degree from The University of Texas School of Law.
His skills include general corporate counsel, life science industry, biotechnology, industry knowledge, pharmaceutical law, bio pharmaceuticals, corporate law, licensing, regulatory compliance. He is also highly experienced at business transactions, commercial contracts, CDMO, CGT, cell and gene therapy.
Philadelphia, PA, USA https://www.crunchbase.com/person/amiel-gross
June 2020 - Present
Amiel Gross serves as Head of Legal at the Center for Breakthrough Medicines at Philadelphia since 2020. He focuses on building and managing the legal function of a rapidly growing biotechnology company in cell and gene therapy manufacturing.
January 2020 - May 2020
Managed internal legal matters for Discovery Labs, a life science real estate holding company, in connection with the spinoff of its core operating business, Center for Breakthrough Medicines, a biotech startup focused on outsourced end-to-end manufacturing of Cell & Gene Therapy drug products.
August 2009 - October 2014
Senior Associate at Dentons, a global law firm driven to provide you with the competitive edge in an increasingly complex and interconnected marketplace.
January 2001 - November 2006
Associate at Orrick, Herrington & Sutcliffe LLP, a global law firm focused on serving the technology & innovation, energy & infrastructure and finance sectors.
2004 - 2006
2002 - 2005
1999 - 2002